ZetaMAST (Zeta-MBC-005) / Zetagen Therapeutics - LARVOL DELTA

Zetagen Therapeutics Announces Peer-reviewed Publication of In-Vivo Dose Optimization Findings for ZetaMast (Zeta-MBC-005) for Triple Negative Breast Cancer Liver Metastases (Businesswire) - "Zetagen Therapeutics...announced today the peer-reviewed publication in PLOS-One of their dose optimization in-vivo study results of ZetaMast (Zeta-MBC-005). Zetagen identified two concentrations of ZetaMast (Zeta-MBC-005) which demonstrated superior effectiveness, reduction in tumor burden, and increased survival rate over control Doxorubicin....Zetagen identifies two concentrations of ZetaMast (Zeta-MBC-005) which were most effective in treating metastatic triple negative breast cancer (TNBC) in the liver. ZetaMast (Zeta-MBC-005) exhibits significant decrease in tumor volume (4-fold) vs. control Doxorubicin. ZetaMast (Zeta-MBC-005) demonstrates a 3.9-fold increase in survival rate over control Doxorubicin with no lung or brain metastases."

Preclinical • Triple Negative Breast Cancer

Zetagen Therapeutics Expands IP Portfolio, Achieving a Milestone of 64 Worldwide Patents in 2024 (Businesswire) - "Zetagen Therapeutics, Inc...announced today in 2024 they nearly doubled their worldwide IP portfolio to 64 patents, spanning across 36 countries including the United States, Europe, Canada, Australia, Japan, United Kingdom, India, Sweden and Switzerland....'Our ambition is to continue growing our intellectual property portfolio with discoveries around the development of Zeta-BC-003 and Zeta-BC-005 for the treatments of metastatic breast cancer, but also for future discoveries towards primary breast cancer treatments'....Additional 34 patents under review including 10 with the USPTO; Including multiple submissions of Composition of Matter for new molecular entities."

Patent • Breast Cancer

Zetagen Therapeutics Shares In-vivo Dose Optimization Data of ZetaMAST (Zeta-MBC-005) Metastatic Breast Cancer in Liver (Businesswire) - "Zetagen identifies two concentrations of Zeta-MBC-005 which were most effective in treating metastatic breast cancer in the liver; Zeta-MBC-005 showed a significant decrease in tumor volume (4-fold) vs. control Doxorubicin; Zeta-MBC-005 demonstrated an increased survival rate (3.9-fold) over control with no lung metastases."

Preclinical • Breast Cancer • Liver Cancer • Oncology